Exclusive: Former Merck scientists raise $85M to map and drug protein interactions in cancer and autoimmune disease

Ryan Cross

Senior Science Correspondent

The surfaces of cells are studded with proteins used to communicate with neighbors and visitors. A new method for mapping them and their interactions is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: Former Merck scientists raise $85M to map and drug protein interactions in cancer and autoimmune disease

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Layoffs at Ginkgo and Xellia; Melodia and Alivexis ink $275M partnership

The Endpoints Slack interview: Saji Wickramasekara on where AI misses the mark — and what's next for Benchling

Scientists just discovered a new genetic clue for delaying Alzheimer’s disease. It’s already inspiring drug ...

Moncef Slaoui joins board at mRNA biotech; Gamida Cell retools with ex-Amryt CEO at the helm

FDA widens Sarepta’s Duchenne gene therapy label to older boys in significant expansion of use

Tectonic enters public markets in one of few biotech reverse mergers this year

Ex­clu­sive: For­mer Mer­ck sci­en­tists raise $85M to map and drug pro­tein in­ter­ac­tions in can­cer and au­toim­mune dis­ease

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

more like this

Lay­offs at Gink­go and Xel­lia; Melo­dia and Alivex­is ink $275M part­ner­ship

The End­points Slack in­ter­view: Saji Wick­ra­masekara on where AI miss­es the mark — and what's next for Bench­ling

Sci­en­tists just dis­cov­ered a new ge­net­ic clue for de­lay­ing Alzheimer’s dis­ease. It’s al­ready in­spir­ing drug ...

Mon­cef Slaoui joins board at mR­NA biotech; Gami­da Cell re­tools with ex-Am­ryt CEO at the helm

FDA widens Sarep­ta’s Duchenne gene ther­a­py la­bel to old­er boys in sig­nif­i­cant ex­pan­sion of use

Tec­ton­ic en­ters pub­lic mar­kets in one of few biotech re­verse merg­ers this year

Exclusive: Former Merck scientists raise $85M to map and drug protein interactions in cancer and autoimmune disease

Layoffs at Ginkgo and Xellia; Melodia and Alivexis ink $275M partnership

The Endpoints Slack interview: Saji Wickramasekara on where AI misses the mark — and what's next for Benchling

Scientists just discovered a new genetic clue for delaying Alzheimer’s disease. It’s already inspiring drug ...

Moncef Slaoui joins board at mRNA biotech; Gamida Cell retools with ex-Amryt CEO at the helm

FDA widens Sarepta’s Duchenne gene therapy label to older boys in significant expansion of use

Tectonic enters public markets in one of few biotech reverse mergers this year